

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/021,818	12/13/2001	Ronald W. Davis	25436/1652	5874
27495 7	590 03/25/2003			
	DODGE, LLP		EXAMINER	
111 HUNTING	M. WILLIAMS / STR STON AVENUE		SULLIVAN,	DANIEL M
BOSTON, MA	02199		ART UNIT	PAPER NUMBER
			1636	1.
			DATE MAILED: 03/25/2003	$\swarrow$

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	_		
		10/021,818	DAVIS ET AL.			
Office Action Summary		Examin r	Art Unit	_		
		Daniel M Sullivan	1636			
	The MAILING DATE of this communication app	pears on the cover she	et with the correspondence address	_		
Period fo	• •	V 10 0ET TO EVDIDE	4 MONTH(S) EDOM			
THE ! - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailined patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, r ly within the statutory minimum will apply and will expire SIX (6 e, cause the application to beco	of thirty (30) days will be considered timely.  MONTHS from the mailing date of this communication.  me ABANDONED (35 U.S.C. § 133).			
1)	Responsive to communication(s) filed on	·	•			
²)□ 2a)□		— · nis action is non-final.				
3)□	Since this application is in condition for allow		I matters, prosecution as to the merits is			
,—	closed in accordance with the practice under					
·	on of Claims	_				
•	<ul> <li>✓ Claim(s) 1-36 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdrawn from consideration.</li> </ul>					
	Claim(s) is/are allowed.					
	Claim(s) is/are rejected.					
·	Claim(s) is/are rejected.  Claim(s) is/are objected to.					
· · · · ·	Claim(s) <u>1-36</u> are subject to restriction and/or	election requirement.				
•	on Papers	•				
9)[	The specification is objected to by the Examine	er.				
10)	The drawing(s) filed on is/are: a)☐ acce	pted or b) objected to	by the Examiner.			
_	Applicant may not request that any objection to the					
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
	The oath or declaration is objected to by the Ex	kaminer.				
•	Inder 35 U.S.C. §§ 119 and 120		2.0. \$ 440(=) (=) == (5)			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
اره	a) All b) Some * c) None of:					
	<ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> </ol>					
	3. Copies of the certified copies of the priority documents have been received in this National Stage					
* S	application from the International Buse the attached detailed Office action for a list	ireau (PCT Rule 17.2	(a)).			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
	) $\square$ The translation of the foreign language $\operatorname{pro}$	* *				
Attachmen	t(s)					
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Noti	view Summary (PTO-413) Paper No(s) ce of Informal Patent Application (PTO-152) er:			

Application/Control Number: 10/021,818 Page 2

Art Unit: 1636

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-9 and 24-26, drawn to a recombinant fusion polypeptide or pair of recombinant fusion polypeptides, classified in class 530, subclass 350.
- II. Claims 10-23 and 27, drawn to a polynucleotide encoding a recombinant fusion polypeptide, a vector and host cell comprising the polynucleotide and a method of using said host cell comprising the polynucleotide, classified in class 435, subclass 71.1.
- III. Claims 28 and 29, drawn to a method of labeling a cell with a fluorescent recombinant fusion polypeptide, classified in class 435, subclass 29.
- IV. Claims 30-36, drawn to a method of monitoring the interaction of two polypeptides of interest, classified in class 435, subclass 29.

The inventions are distinct, each from the other because of the following reasons:

The nucleic acids of Invention II are related to the protein of Invention I by virtue of encoding the same. The DNA molecule has utility for the recombinant production of the protein in host cells. Although the DNA molecule and protein are related since the DNA encodes the specifically claimed protein, they are distinct inventions because they are physically and functionally distinct chemical entities, and the protein product can be made by another and materially different process, such as by synthetic peptide synthesis or purification from the

Application/Control Number: 10/021,818

Art Unit: 1636

natural source. Further, the DNA may be used for processes other than the production of the protein, such as nucleic acid hybridization assay.

Inventions III and IV are distinct methods. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different methods are not disclosed as capable of use together in a single process and have different modes of operation and effects as the method of monitoring the interaction of two polypeptides would clearly comprise method steps, such as the introduction of first and second polypeptides labeled with florescence donor and acceptor molecules, which are not required in the method of labeling a cell.

Each of Groups I and II are related to the methods of Inventions III and IV as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products can as claimed can be used in each of the materially different processes of Groups III and IV.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

Application/Control Number: 10/021,818

Art Unit: 1636

. . . .

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448.

The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Remy Yucel, Ph.D. can be reached on 703-305-1998. The fax phone numbers for the

organization where this application or proceeding is assigned are 703-746-9105 for regular

communications and 703-746-9105 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

dms

March 20, 2003

Anne-Marie Falk ANNE-MARIE FALK, PH.D

Page 4